申请人:Health Innovation Ventures B.V.
公开号:US10202408B2
公开(公告)日:2019-02-12
The invention relates to compounds of use as targeted cytotoxic agents and methods of use thereof. In particular, the invention relates to prodrugs that are substantially resistant to human AKR1C3 enzyme metabolism, methods of cell ablation using said compounds and methods of treatment of cancer and other hyperproliferative disorders using said compounds.
本发明涉及用作靶向细胞毒剂的化合物及其使用方法。特别是,本发明涉及对人类 AKR1C3 酶代谢具有实质性抗性的原药、使用所述化合物进行细胞消融的方法以及使用所述化合物治疗癌症和其他过度增殖性疾病的方法。